Accessibility Menu

Latigo Biotherapeutics(NASDAQ) LTGO

Market Cap$1.53BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+33%
5 YearN/A
1 YearN/A
1 MonthN/A
$21.86
-9.78%
-2.37Today
After hours$21.69-$0.17 (-0.78%)
Latigo Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 22.022026-08-31
Latigo Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.09%USD 22.002026-08-24
Since inception+32.77%USD 18.252026-08-07

Latigo Biotherapeutics Financials at a Glance

Market Cap

$1.53BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$43.91

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-3.14 (Low)

Price

$21.86

Volume

155,037.851

Open

$24.41

Previous Close

$22.02

Daily Range

$21.75 - $24.70

52-Week Range

$17.22 - $25.93

Estimated Earnings Date

N/A

LTGO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative non-opioid pain medicines. The company aims to provide effective solutions for pain management without the risk of addiction, addressing a significant need in the healthcare sector.

Products and Services
  • Molecule: LTG-001, a non-opioid pain relief option
  • Molecule: LTG-32, targeting rapid pain transmission cessation
  • Molecule: LTG-418, designed for intravenous administration
Growth Outlook
  • Market demand for non-opioid pain management is increasing
  • Clinical trials are progressing, enhancing product validation
  • Strategic partnerships may expand market reach and capabilities
Financial Highlights
  • Market capitalization stands at approximately $1.1 billion
  • Stock price has fluctuated between $18.19 and $22.47 this year
  • Recent trading volume reached over 3.2 million shares
Latigo Biotherapeutics Inc. is positioned in a growing market that seeks alternatives to traditional opioid medications. The company's innovative product pipeline, including LTG-001 and LTG-32, addresses urgent healthcare needs while minimizing addiction risks. With a solid market capitalization and significant trading activity, Latigo is attracting attention from investors looking for opportunities in the biopharmaceutical sector. The ongoing clinical trials and potential partnerships further enhance the company's growth prospects, making it a noteworthy entity in the healthcare landscape.
AI Generated • Aug 7, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

59

CEO

Nima M. Farzan, MBA

Website

www.latigobio.com

Headquarters

Thousand Oak, CA 91320, US

LTGO Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$1.53BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

63.24M

Volume

155.04K

Avg. Volume

398.62K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Latigo Biotherapeutics Performance Analysis

Latigo Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Latigo Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.97N/A
20252025-12-31USD -1.7378.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$0.05

N/A

Gross Margin

N/A

N/A

Market Cap

$1.53BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

59

N/A

Net Income

-$22.96

N/A

EBITDA

-$23.39

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$42.92

N/A

Total Debt

$0.55

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.05

N/A

Short Term Debt

$0.50

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$27.07

N/A

Operating Cash Flow

-$27.07

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About LTGO

What is the current price of Latigo Biotherapeutics?

Latigo Biotherapeutics is trading at $22.02 per share.

What is the 52-week range for Latigo Biotherapeutics?

Over the past 52 weeks, Latigo Biotherapeutics has traded between $17.22 and $25.93.

How much debt does Latigo Biotherapeutics have?

As of the most recent reporting period, Latigo Biotherapeutics reported total debt of $554.00K.

How much cash does Latigo Biotherapeutics have on hand?

Latigo Biotherapeutics reported $42.37M in cash and cash equivalents in its most recent financial results.

What is Latigo Biotherapeutics’s dividend yield?

Latigo Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services